Shark cartilage extract produces no anti-cancer effects in latest study
Results of a new study led by Charles Lu of the University of Texas MD Anderson Cancer Center in Houston defies the alternative hypothesis that shark cartilage extract has anti-cancer effects in lung cancer patients.
METHODS
This study involved 397 participants with non–small cell lung cancer.
- Half received AE-941 (Neovastat, shark cartilage extract)
- Half received a placebo
- All 397 patients also received radiation and chemotherapy.
RESULTS
The AE-941 shark cartilage extract exhibited no effect on:
- progression of cancer
- tumor response
- length of survival
CONCLUSIONS
This study, carried out by a highly reputable cancer center and published in a peer-reviewed journal, should give oncologists research on shark cartilage extract to point out to their patients seeking answers about whether or not shark cartilage extract contains any anti-cancer effects.
PUBLICATIONS
This study appears in the June 16 issue of the Journal of the National Cancer Institute.
Source: ScienceNews.org
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
